House Subcommittee Hearing Explores Alleged Gaps In Cosmetic Safety
This article was originally published in The Rose Sheet
Executive Summary
Legislative proposals that would require cosmetics companies to report adverse events to FDA and register their manufacturing facilities were the focus of discussion among panelists testifying on Capitol Hill May 14 on a draft version of the Food and Drug Administration Globalization Act of 2008
You may also be interested in...
2018 In Review: US Midterm Mania Stifles Cosmetics Regulatory Reform Momentum
Despite repeated stakeholder assertions of being “closer than ever” to modernizing cosmetics regulations, the 115th Congress ended with reform legislation stranded in committee. The Personal Care Products says midterm elections diverted lawmakers’ attention from unresolved issues, likely including possible preemption terms to put a lid on growing state and local requirements.
What Does FDA Deem A "Serious Adverse Event"? Matrixx Learns The Hard Way
A narrower interpretation of "serious adverse event" - compared with FDA's definition - is costing Matrixx Initiatives at least $10 million dollars with the recall of its intranasal Zicam products - assuming FDA cannot be convinced to reverse its position
What Does FDA Deem A "Serious Adverse Event"? Matrixx Learns The Hard Way
A narrower interpretation of "serious adverse event" - compared with FDA's definition - is costing Matrixx Initiatives at least $10 million dollars with the recall of its intranasal Zicam products - assuming FDA cannot be convinced to reverse its position